![](https://tracker.live.rns-distribution.com/track.live-rns/4813355_75d1671758db0ed18eba2dbba83793b2.png)
Rentokil Initial plc (the Company)
The Company hereby announces that David Frear, Non-Executive Director, purchased 250 American Depositary Shares (ADSs) in the Company at a price of US$39.4998 per ADS on 22 June 2023. Each ADS is equivalent to five of the Company's ordinary shares of one pence each.
The notification set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| David Frear
| ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Non-Executive Director | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| Rentokil Initial plc | ||||
b)
| LEI
| 549300VN4WV7Z6T14K68 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Rentokil Initial plc American Depositary Shares
CUSIP: 760125104 | ||||
b)
| Nature of the transaction
| Purchase of American Depositary Shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Total price
|
250
$9,874.95 | ||||
e)
| Date of the transaction
| 22 June 2023 | ||||
f)
| Place of the transaction
| New York Stock Exchange |
Enquiries:
Catherine Stead, Company Secretary Rentokil Initial plc +44 (0)7826 533700
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.